Background/aims: Cardiovascular outcome trials, among others, aim to assess the beneficial effects of a treatment on multiple event-time outcomes, such as the time to a myocardial infarction and the time to a stroke. The traditional approach is to conduct a simple analysis of a composite outcome defined as the time to the first component event using a logrank test or the Cox Proportional Hazards regression model. This ignores information from other component events after the first. The composite outcome analysis also treats all initial outcome events as equally important, for example, non-fatal myocardial infarction is as important as cardiovascular death. Methods: Herein, we describe the application of the Wei-Lachin multivariate one-sided (or one-directional) test to the analysis of multiple event-time outcomes. The test is based on the unweighted mean of the treatment group coefficients from individual Cox proportional hazards models fit to the outcomes, where the covariance of the set of coefficients is obtained from a partitioning of the information sandwich estimate. A weighted test is also described, weighing the outcomes by a scoring of their clinical importance. These and other methods are compared with application to the Prevention of Events with Angiotensin-Converting Enzyme Inhibition cardiovascular outcome study. Results: The Wei-Lachin test provides an inference with strong control of the type 1 error probability on the difference between groups for the set of outcomes considered. However, it does not provide an inference on the individual components specifically with control of the overall type 1 error probability. By direct computation of relative efficiency and by simulation, we show that the power of the Wei-Lachin one-directional test can be greater than that of the traditional composite outcome analysis based on the time to the first observed component event. Conclusion: The Wei-Lachin multivariate one-directional test may be more powerful than the traditional analysis of a composite outcome defined as the time to the first component outcomes experienced by each subject.
Introduction
In a cardiovascular (CV) outcomes trial, subjects may experience a major adverse cardiovascular event (MACE) usually defined as the time to non-fatal myocardial infarction (MI), non-fatal stroke, or CV death, whichever occurs first. Often, a MACE+ outcome is employed that includes other related outcomes such as a revascularization procedure, hospitalization for unstable angina, or hospitalization for congestive heart failure (CHF). The traditional analysis, commonly termed a composite analysis, consists of standard survival analysis of the time to the first event so that each subject contributes a single event or right censored time. However, this fails to capture the total burden of disease, such as when a revascularization procedure is followed by CV death, the latter not entering into the analysis. This may also sacrifice power.
Other methods for the analysis of composite outcomes include the weighted composite of Bakal et al., 1 the Win Ratio, 2 and the ordered risk profile. 3 All three methods attempt to compare the treatment groups with respect to the incidence of the component events and their relative importance or severity in a manner that is clinically meaningful both to physicians and to patients. Others have proposed analyses of the individual components with an adjustment for multiple tests, or using a gatekeeping strategy based on an a priori specified order of testing, or apportioning the type 1 error probability over primary and secondary outcomes (see Alosh et al. 4 ).
Herein, we describe a simple test, originally proposed by Wei and Lachin, 5 that can provide a more powerful approach to the analysis of multiple event times. The method can also employ weights to reflect the perceived relative severity of each outcome. The method is applied to a past-completed CV outcomes study.
The Wei-Lachin one-directional multivariate test
Background
Wei and Lachin 5 describe a multivariate analysis of a vector of K two-group Aalen-Gill or weighted logrank statistics for K event times, where each subject can experience one or more of the K events. In addition to the usual K-df multivariate analysis of variance (MANOVA)-like omnibus test, they suggested that a simple sum of the rank statistics could provide a 1 df test of the joint null hypothesis for the K outcomes against a restricted alternative hypothesis of ''stochastic ordering'' wherein the distribution function for each outcome in one group dominates that of the other. This alternative implies that the values of the K outcomes for one group tend to be less than those of the other, although not necessarily to the same degree. This alternative hypothesis is also called a one-directional or multivariate one-sided hypothesis.
The Wei-Lachin one-directional test can then be applied to any vector of statistics comparing two groups for multiple outcomes. Lachin 6 described the application to the analysis of repeated measures using summary statistics such as the mean difference or the Mann-Whitney difference parameter estimate. Lachin 7 describes the application to the analysis of multiple outcomes, possibly measured on different scales, such as to a joint analysis of means, proportions, and lifetimes, and more generally to any set of model-based analyses.
Application to multiple event times under proportional hazards
The Wei-Lachin 1 df one-directional test is described in terms of the sum or simple mean of the differences between groups in a set of summary measures. Herein, since the analysis is conducted under proportional hazards (PH) assumptions, the test is described in terms of the estimated log hazard ratio or the group coefficient b b j for the jth outcome, where a negative value represents a reduction in risk with the experimental therapy (E) versus control (C). The coefficient estimates are obtained by fitting a separate PH regression model, perhaps covariateadjusted, for each outcome, for example, time to the first non-fatal MI, time to first non-fatal stroke, and time to CV death, where any one patient could have an event in any or all of the component analyses.
For simplicity, consider the case where each subject can experience either or both of two events A and B, with log hazard ratios b a and b b , respectively, for experimental versus control E:C. These hazard ratios are conveniently estimated from separate Cox PH models to yield a vector of coefficient estimates b 8 then show that the model-based analysis can provide an estimate of the covariances of the parameter estimates by partitioning the information matrices from the two models (see also Lachin 7 ) . Thus, the estimated covariance matrix of the vector of coefficient estimates can be obtained from the two modelŝ
The covariance is provided by supplemental programming or by the mmm function in the R package multcomp. Asymptotically, under the marginal PH model assumption, b
b is distributed as bivariate normal with expectation b and covariance matrix S, each of which is estimated consistently from the model-based estimates.
Then, the null and alternative hypotheses of interest are
Thus, H 1S designates that the experimental therapy is at least as effective as control for both outcomes and is superior to control for either or both outcomes. This is called the multivariate one-directional alternative hypothesis.
The null hypothesis H 0 can be tested against the restricted alternative H 1S using the simple Wei-Lachin test of the form
where J = ( 1 1 ) 0 . Asymptotically, Z S ;N (0, 1) under H 0 from Slutsky's theorem. Since a negative value for b b (or Z S ) favors the treatment, the test rejects H 0 in favor of H 1S when Z S Z a at level a one-sided. The test Z S can also be expressed as the ratio of the unweighted mean coefficient b b relative to its SE (see below).
The alternative hypothesis H 1S states that there is a preponderance of benefit for E relative to C, that leads to the one-sided rejection region for the test. However, it is possible to conduct a two-sided one-directional test that either E is superior to C or C is superior to E: In that case, the Wei-Lachin 1 df test statistic Z S is referred to the two-sided critical value rather than the one-sided value to determine statistical significance. Herein, we describe the one-sided test.
Also, note that the test can also be generalized to employ a weighted combination of the estimates of the form
where W 0 J = 1. The weights (pre-specified) can reflect the relative importance or severity of the different outcomes or be determined by statistical optimality criteria. Thus, the test can be described in terms of the weighted average of the group coefficient estimates, b b w , relative to its standard error. This also provides a summary measure of the overall difference between groups for which one-or two-sided confidence limits can be provided. For
is simply the unweighted mean of the coefficients that provides the same test as in equation (3).
Application under non-PH models
The above test applies under the assumption that the model is correctly specified for each outcome, that is, the PH assumption applies. When the model specifications may not apply, Lin and Wei 9 describe a robust information sandwich estimate of the covariance matrix of the coefficient estimates.
Wei et al. 10 then show that partitioning of the robust covariance matrices from separate models can be used to provide the joint covariance matrix of the parameter estimates from the separate models. Their approach also fits separate marginal models to provide estimates of b b a and b b b and then uses the Lin and Wei 9 robust estimate of the covariance matrix to obtain the covariance estimate b s ab . The Wei-Lachin 1 df onedirectional test can then be computed from this joint covariance matrix.
Lin 11 also describes a joint model that can be estimated under the ''working'' model assumption of independence of the two outcomes, again with a consistent estimate of the covariance matrix obtained from the robust information matrix. These methods provide consistent estimates for the coefficients and the covariance matrix when the PH model assumptions do not strictly apply.
Another possible consideration is that CV death is a competing risk for other non-fatal outcomes. Nevertheless, a Cox PH model analysis in which nonfatal event times are censored by death can still be justified since Prentice et al. 12 have shown that such a PH model provides an evaluation of covariate effects on the underlying cause-specific hazard for the event. Alternately, it would be possible to employ the Fine and Gray 13 generalization of the PH model for the analysis of competing risks. Herein, the simple PH model is employed.
The method could also be generalized to include all events of all types in all subjects using the multiplicative intensity model generalization of the Cox PH model for recurrent events. Some have suggested, however, that recurrent events of a specific type could reduce power because a subject who has experienced an initial event of a specific type (e.g. non-fatal MI) may then be at high risk of additional events of that type, and that risk may not be affected by treatment.
Relative efficiency versus a composite outcome analysis
Theoretically, for every alternative hypothesis defined by a specific pair of values for b a and b b , there is an optimal linear weighted statistic of the form in equation (4) with weights that maximize the power to detect a difference between groups. However, the actual values of the parameters, and thus of the optimal weight vector, are unknown. Nevertheless, under mild conditions, Frick 14, 15 shows that the Wei-Lachin test is a robust or maximin test that maintains good power over a range of parameter values. See Lachin 7 for technical details.
Lachin 7 then describes the power of a Wei-Lachin test of two event-time outcomes under a bivariate exponential model with a shared frailty that would apply approximately to an analysis using a test based on multiple Cox PH models with correlated event times. The Supplemental Appendix also derives the hazard rate for a time-to-first-event composite outcome that can be used with the equations of Lachin and Foulkes 16 to assess sample size or power for the composite analysis.
For a specified set of hazard rates, Lachin 7 shows that a total N = 394, evenly divided between groups, provides a one-sided one-directional Wei-Lachin test with 90% power to detect hazard ratios of HR a = 0:8 and HR b = 2=3. Under this same model, the composite outcome would have a hazard ratio HR m = 0:7 and the analysis would require a total N = 436 to provide 90% power with a one-sided test at the 0.05 level. Since the relative efficiency of two tests is proportional to the ratio of the sample sizes needed to provide a given level of power, for this example, the Wei-Lachin test of the two outcomes has a relative efficiency of 1.11 relative to the composite outcome test, or an 11% greater efficiency.
A simulation study of the relative power of the Wei-Lachin test versus the composite analysis is presented in Supplemental Appendix B. The results show that the Wei-Lachin test is largely more powerful than the standard approach in cases of practical interest where the treatment effect is in the same direction for both outcomes, that is, the log HRs log(HR a ) and log(HR b ) have the same sign.
Example-the Prevention of Events with Angiotensin-Converting Enzyme Inhibition study
The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) study 17 assessed whether treatment with angiotensin-converting enzyme (ACE) inhibition with trandolapril (angiotensin-converting enzyme inhibitor (ACEi), n = 4158) versus placebo (n = 4132), when added to standard therapy, would reduce the risk of CV outcomes in patients with stable coronary artery disease. The primary outcome was the composite of death from CV causes, non-fatal MI, or coronary revascularization. Over an average of 4.8 years of follow-up, the primary outcome was observed in 21.9% in the ACEi group versus 22.5% in the placebo group, with a hazard ratio of 0.96 (95% confidence interval: 0.88-1.06; p = 0.43 two-sided (0.22 one-sided). Table 1 presents the numbers of subjects (cases) with each type of event. In addition to the primary outcome, we also analyze two other composite outcomes: traditional MACE consisting of CV death, non-fatal MI, or non-fatal stroke, and MACE + CHF consisting of either a MACE outcome or hospitalization for CHF. For all analyses, one-sided p-values are shown, although in practice two-sided values might be employed.
Among the components of the primary outcome, there is a small benefit with ACEi versus placebo for CV death and revascularization, but a slight benefit with placebo for non-fatal MI. As a result, there is a small non-significant benefit with ACEi for the composite primary outcome. However, there is a nominally significant (one-sided) benefit with ACEi for non-fatal stroke, so the traditional MACE outcome (CV death, non-fatal MI, or stroke) shows greater benefit for ACEi than did the primary outcome. There was also a nominally significant benefit of ACEi with CHF, and the composite of MACE + CHF showed an even greater suggestion of benefit with a HR = 0.9 and one-sided p = 0.06.
To conduct Wei-Lachin analyses, separate Cox PH models were fit for the component events within each composite outcome and the R function mmm used to provide the estimated covariance matrix of the treatment group coefficients. The coefficients and covariance matrix are presented in Supplementary Appendix Table 1 . The unweighted mean of the coefficients for the components of each composite outcome and its SE were obtained. From these, the Wei-Lachin onedirectional tests were then computed for the set of components of each composite outcome, with the results shown in Table 2 .
For the primary outcome, there is essentially no difference between groups for any of the three component outcomes (Table 1) , and the Wei-Lachin test provides a larger one-sided p-value than did the composite outcome analysis ( Table 2 ). For the MACE and MACE + CHF analyses, both of which showed a non-significant but beneficial trend with treatment in the composite analyses, the Wei-Lachin p-values were smaller and, in the case of MACE + CHF, would have yielded a statistically significant result either oneor two-sided (0.016 or 0.033). 
Alternative methods
The model-based Wei-Lachin test is not the only alternative analysis to the standard composite approach. In the following, additional methods are described with application to the MACE + CHF outcome.
Robust marginal models
Wei et al. 10 were among the first to show that the covariance matrix of the coefficients from multiple models could be obtained by partitioning the Lin and Wei 9 robust information sandwich. Their method is provided by the SAS procedure PHREG or the coxphreg function in the R survival package (see also Therneau and Grambsch 18 ). However, neither program provides the joint covariance matrix of the parameter estimates from the multiple models that would be required to compute the Wei-Lachin test. Rather, additional computations are required as described in the older SAS program wlw.sas. For the above example, the results using the Wei-Lin-Weissfeld approach using either SAS or R are virtually identical to the Wei-Lachin test using the model-based covariance matrix estimate described above.
Multivariate tests
Other tests might be considered that are directed toward a different specification of the alternative hypothesis. The most general test is the T 2 -like MANOVA test on K-df that is directed toward the omnibus alternative hypothesis H 1O :(b a , b b ) 6 ¼ (0, 0) of a group difference in either direction (benefit or harm) for either or both outcomes. For the case of a test of two means, Lachin 7 shows that the Wei-Lachin sum test is more powerful than the omnibus test, or separate tests with a multiplicity adjustment, when the restricted alternative hypothesis H 1S in equation (2) applies.
For the PEACE study MACE + CHF outcome(s) described above, the MANOVA test provides a chisquare value of 7.39 on 4-df with p = 0:117. Further, Table 1 , clearly none of the separate tests for the individual outcomes would approach statistical significance with a correction for multiplicity.
Another approach is based on the restricted alternative H 1A :b a = b b = b 6 ¼ 0 which assumes that the expected value of the treatment group coefficient (or HR) is the same for each outcome. In that case, an efficient test of H 0 versus H 1A is provided by a weighted average of the form in equation (4) with weights that are inversely proportional to the variances, of the form
This computation is provided by the SAS PHREG using the ''average'' option. Note that this alternative hypothesis is more restrictive than the one-directional alternative to which the Wei-Lachin test is directed. For the PEACE study MACE + CHF outcome, this yields a common coefficient estimate of b b A = À0:1059, or a hazard ratio of 0.90, with SE = 0:0602 and a corresponding Z-test value of 21.76 with a one-sided p = 0:04.
Alternately, since the Wei-Lin-Weissfeld approach is fit using a PH model that is stratified with a distinct background hazard function for each outcome, the set of models can be fit using a single group coefficient for all outcomes (see Therneau and Grambsch 18 ) . When applied to the PEACE MACE + CHF outcome, this approach provides an estimate of the assumed common coefficient b b = À 0:1070, or HR = 0.90, with SE = 0:068 and one-sided p = 0:06. The results are similar to the results obtained from the weighted average of the separate coefficients for each outcome using the weights in equation (5) .
Weighted Wei-Lachin analyses
The weighted Wei-Lachin test in equation (5) could also be conducted using a weighted average of the coefficients for the different outcomes with weights that reflect the perceived importance or severity of each outcome. For example, Bakal et al. 1 employed weights 1.0 for CV death, 0.5 for non-fatal stroke, 0.3 for hospitalization for CHF, and 0.2 for non-fatal MI. The corresponding weight vector, rescaled to sum to 1, has elements W = ( 0:5 0:25 0:15 0:1 ) 9 for each component event. The weighted test then yields a weighted average b b w = À 0:036 corresponding to an HR = 0.965 with 95% two-sided limits of 0.927 and 1.003 and one-sided p = 0:037.
Discussion
The objective of an analysis of multiple event-time outcomes, as in the PEACE CV outcomes study, is to assess whether the experimental treatment provides a preponderance of benefit for a set of outcomes rather than any one specific outcome. Heretofore, the most commonly used approach has been to construct a composite outcome defined as the time to the first of the component events. Herein, we describe a simple Wei-Lachin test that is based on separate analyses of each component outcome event, not just the first of all component events as in the composite outcome analysis. The test is expressed as the simple sum of the group coefficient estimates over all outcomes or their average. Through application to the PEACE study, and computations of power and simulations, we demonstrate that the simple Wei-Lachin test can provide greater power than the composite analysis.
It would also be possible to further extend the Wei-Lachin test to the analysis of all recurrent component events over time using the multiplicative intensity model extension of the Cox PH model or the robust counterpart proportional rate model. 19 Unfortunately, the recurrent event times were not included in the publicly available PEACE study data set, and it was not possible to illustrate analyses of all recurrent events.
On the other hand, methods such as the Wei-Lachin analysis that employ multiple event times may not be desirable in situations wherein the occurrence of an event of one type often prompts a change in therapy administered to a patient. Under an intent-to-treat or pragmatic trial design, anything that happens to the patient after randomization can be viewed as part of the ''real-life'' experience with an initial treatment assignment. However, a change in treatment prompted by an outcome event obviously limits the ability to ascribe outcomes to the pharmacologic or other mechanism of the agent. None of these methods are designed to account for such a change in treatment. In this case, the time-to-first event composite analysis will in fact be less affected by the change in treatment than the Wei-Lachin or other methods, and on that basis might be preferred.
As in the traditional composite analysis, it is then desirable to evaluate the treatment group effect on each component outcome separately in a set of secondary analyses, involving multiple estimates and tests. Usually, these component-wise inferences are considered descriptive and no adjustment for multiple tests is applied.
In conclusion, the Wei-Lachin simple sum test is directed to testing the joint null hypothesis of no difference for multiple outcomes against the restricted onedirectional alternative hypothesis that the treatment has a preponderance of positive effects on the multiple outcomes considered, while not being harmful for any. The test has good power when such one-directional differences are observed and may be more powerful than the traditional composite analysis of the time to the first observed outcome event.
